A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac
A phase 2 trial of Selinexor, Dexamethasone, Bortezomib in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
Overview
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. is a phase 2 interventional study registered as NCT04414475 by Karyopharm Therapeutics Inc, with 127 participants planned, started 2020-07-01 and due to reach its primary completion in 2028-01. Interventions recorded: Selinexor, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
- TrialSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Shares Karyopharm Therapeutics, Selinexor.
- TrialA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly
Shares Karyopharm Therapeutics, Selinexor, Dexamethasone.
- TrialXPORT-EC-042 / ENGOT-EN20 / GOG-3083
Shares Karyopharm Therapeutics, Selinexor.
- TrialStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Shares Karyopharm Therapeutics, Selinexor.
- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Selinexor, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Dexamethasone, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Bortezomib, Dexamethasone, Multiple myeloma.